Subsequent thoracic cancers among patients diagnosed with lung cancer: a SEER database analysis

Abdel‐Rahman, Omar; Cheung, Winson Y.

doi:10.1080/03007995.2017.1333953

Cited by 16 publications

(31 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, patients with lung HGNEC had elevated risks of getting leukemia and cancers of the oral cavity and pharynx, colon and rectum, esophagus, pancreas, urinary bladder, kidney and renal pelvis, and lung and bronchus. Cancer risk reduction in these patients is consistent with prior researches, which are relevant to lung cancer and non-small cell lung cancer [11,12]. Although the causes of risk reduction are not well understood, they may be associated with patient age at diagnosis of SCLC.…”

Section: Discussionsupporting

confidence: 89%

Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)

Zhang

Tao

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: Pulmonary high-grade neuroendocrine carcinoma (HGNEC) has a rising incidence of developing second primary malignancies (SPMs). This study is the first population-based analysis to quantify the SPM risks among survivors of lung HGNEC. Methods: We used the Surveillance, Epidemiology, and End Results (SEER) database to calculate standardized incidence ratio (SIR) and absolute excess risk (AER) between 2000 and 2016 for patients with pulmonary HGNEC. Results: The data of 1161 patients with SPMs were retrieved from the SEER database. The ratio of observed/ expected number of SPMs in pulmonary HGNEC was 1.53. Solid tumours comprised 91% of all second malignancies in lung HGNEC patients, with the most common cancers reported in the oral cavity and pharynx, the urinary and respiratory systems Conclusions: Our study observed an increased risk of SPMs among patients with pulmongnancies.

show abstract

Section: Discussionsupporting

confidence: 89%

Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)

Zhang

Tao

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…focused on early(I/II) lung cancer patients with radiotherapy alone. The present studies demonstrated that early lung cancer patients harbored higher risk of metachronous SPLC compared with advanced lung cancer patients because the longer survival time after successful treatment of lung cancer gave such patients more chance for development of metachronous SPLC 24,25 . Our study also confirmed that the IPLC patients IPLC at stage I with 0.98% per year were associated with a highest risk of developing metachronous SPLC than those in the advanced stage groups.…”

Section: Discussionmentioning

confidence: 60%

“…However, our study suggested that the risk of developing metachronous SPLC for IPLC patients with radiotherapy was lower compared with that of patients without radiotherapy in the first 5 years follow-up period, which was consistent with the study of Abdel-Rahman et al . 25 . Even when we adjusted various factors of metachronous SPLC through propensity score matching analysis, this decreased risk of metachronous SPLC in the radiotherapy group still remained.…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy was associated with the lower incidence of metachronous second primary lung cancer

Tian

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Our study aims to estimate the incidence of metachronous second primary lung cancer(SPLC) in initial primary lung cancer(IPLC) survivors and to determine whether radiotherapy affects the risk of metachronous SPLC in the first five years after the diagnosis of lung cancer. Incidence data of IPLC individuals who survived ≥2 years were obtained from SEER-18 database in 2004–2007. Joinpoint regression analysis and competing risk analysis were used to calculate the incidence of metachronous SPLC. Propensity score matching and decision analysis were available to estimate the effect of radiotherapy on metachronous SPLC. 264 of 11657 IPLC survivors with radiotherapy and 1090 of 24499 IPLC survivors without radiotherapy developed metachronous SPLC during 5-year follow-up, respectively. In joinpoint regression analysis, the 5-year incidence of metachronous SPLC in the radiotherapy group was lower than that in the nonradiotherapy group(2385 per 100,000 vs 4748 per 100,000, HR = 0.43,95% CI:0.39–0.47). Competing risk analysis showed that the survivors with radiotherapy were associated with the lower 5 year incidence of metachronous SPLC compared with those without radiotherapy(2.28% vs 4.47%, HR = 0.49,95% CI:0.43–0.57). Through propensity score matching, 4077 pairs of survivors were available to further study that radiotherapy potentially decreased the risk of developing metachronous SPLC with the adjustment of various factors(2.5% vs 3.3%, HR = 0.72, 95% CI:0.55–0.96). Decision analysis suggested that radiotherapy was a negative independent risk factor of metachronous SPLC with clinical net benefit in a range of risk thresholds (2% to 5%). Survivors of IPLC with radiotherapy likely had a low risk of metachronous SPLC during the first five years follow-up, especially non-small cell lung cancer.

show abstract

“…In our current study, the incidence of SPC after NSCLC was lower than Hayat et al, and the probable reason might be because we excluded patients with history of malignant disease. The highest morbidity of SPCs after the diagnosis of NSCLC was lung cancer (45.1%), which might be due to the risk factors that cause lung cancer still exist (15). The second most common SPC was prostate cancer followed by colon and rectum cancer, which was similar to the incidence of these cancers in the general population (1).…”

Section: Discussionmentioning

confidence: 69%

Effect of second primary cancer on the prognosis of patients with non-small cell lung cancer

Cui

Tian

et al. 2019

J. Thorac. Dis

View full text Add to dashboard Cite

Background: Second primary cancer (SPC) is not a rare event for patients with non-small cell lung cancer (NSCLC), especially for those who survive for a longer period of time. This study was aimed to explore the effects of SPC on the survival of NSLCL patients. Methods: A total of 241,805 patients with primary NSCLC were identified between 2004 and 2014 from the Surveillance, Epidemiology, and End Results (SEER) database. The incidence of SPC and its effect on the overall survival (OS) and lung cancer-specific survival (LCSS) was explored and analyzed using Cox regression model with SPC being treated as a time-dependent covariate. Results: The incidence of SPCs after the diagnosis of NSCLC was 6.4%, with the second primary lung cancer being the most common one (45.1%). About half of the SPCs (50.7%) occurred during the first year after the diagnosis of NSCLC. It seemed that patients who developed SPC late in the follow-up period tended to have poor prognosis. Multivariable analysis with Cox regression showed that the occurrence of SPC was a poor prognostic factor for patients with NSCLC [hazard ratio (HR), 1.298; 95% confidence interval (CI), 1.270-1.326; P=0.000], and it increased the risk of LCSS (versus no SPC, HR, 1.094; 95% CI, 1.066-1.123; P=0.000). Conclusions: The occurrence of SPC after the diagnosis of NSCLC was not a rare event, and it indicated a poorer prognosis compared with patients without it. During the follow-up, attention should be paid to the screening of SPC especially the second primary lung cancer, and a rational surveillance policy should be formed and implemented.

show abstract

Subsequent thoracic cancers among patients diagnosed with lung cancer: a SEER database analysis

Abstract: There is an excess risk for the development of esophageal cancer and second primary lung cancer following an initial lung cancer diagnosis. This risk is present irrespective of gender or receipt of radiotherapy.

Cited by 16 publications

References 12 publications

Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)

Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)

Radiotherapy was associated with the lower incidence of metachronous second primary lung cancer

Effect of second primary cancer on the prognosis of patients with non-small cell lung cancer

Contact Info

Product

Resources

About